Clinical features, treatments, and outcomes in inflammation-associated non-rapidly-progressive coronary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

A cohort of adults with INR-CAD will be enrolled at Peking Union Medical College Hospital and followed prospectively. Investigators will collect clinical histories, angiography results, serial inflammation markers or autoantibodies, treatment details (lifestyle measures, secondary prevention, immunosuppressive therapy, and revascularization), and clinical outcomes including disease progression, restenosis, and major cardiovascular events. Serial laboratory tests and imaging will be used to document progression and treatment response over time. The study aims to define the clinical phenotype of INR-CAD and identify treatment patterns associated with better or worse outcomes.

Why it matters

Who can join: the full rules

Inclusion criteria

1. 18 years of age or older, male or female.
2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).
3. Meeting the clinical diagnostic criteria for INR-CAD, including: (1) Angiographic evidence of coronary lesions (≥ 50% diameter stenosis, de novo or restenotic); (2) Evidence of chronic inflammation within 24 months: (A) Positive inflammatory markers (erythrocyte sedimentation rate \[ESR\], high-sensitivity C-reactive protein \[hs-CRP\], interleukin-6 \[IL-6\], tumor necrosis factor-alpha \[TNF-α\], et al; at least twice, ≥ 12 weeks apart), or (B) Positive autoantibodies (at least twice, ≥ 12 weeks apart), or (C) Established diagnosis of chronic inflammatory diseases (autoimmune disease, systemic vasculitis, psoriasis, tuberculosis, et al), or (D) Receiving immunosuppressive therapy (glucocorticoids, immunosuppressive agents, et al).
4. NOT meeting the clinical diagnostic criteria for IR-CAD, including: (1) Hospitalization due to myocardial ischemia, including: (A) Typical symptoms of angina (Canadian Cardiovascular Society \[CCS\] III-IV), and (B) Non-invasive evidence of myocardial ischemia; (2) Angiographic evidence of new or worsened coronary lesions (de novo or restenotic) considered relevant to myocardial ischemia, which occurred: (A) Within 6 months of last coronary angiography in any patients, or (B) Within 12 months of last coronary angiography in patients receiving immunosuppressive therapy within 24 months.
5. Received, or are receiving, or will receive the 24-month clinical follow-up defined by the clinical follow-up protocol for INR-CAD.

Exclusion Criteria:

1. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).
2. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).
3. Vital organ failure.
4. Life expectancy \< 1 year.
5. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.
6. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).
7. Previous enrollment in this study.
8. Participation in another study within 30 days.
9. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).
10. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Zhenyu Liu, M.D.
• Email: Pumch_lzy@163.com
• Phone: +861069155068

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating characteristics of a special type of coronary artery disease

  This study is trying to understand the unique features of a fast-progressing type of coronary artery disease by comparing patients with this condition to those with a more common form of the disease.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06007248

• Evaluating comprehensive treatment for rapidly-progressive coronary artery disease

  This study is testing a new treatment plan for people with rapidly-progressive coronary artery disease that includes medication and procedures to see if it helps them feel better and manage their condition.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05860400

• Evaluating vessel imaging for coronary artery disease

  This study is testing if a special imaging technique can help doctors better understand plaque in the arteries of people with heart issues and see how it relates to blood flow.

  Recruiting Medical University of Warsaw · Warsaw, Mazowieckie Voivodenship · NCT06844942

• IRIS Coroflex NEO stent registry

  This project tests whether Coroflex ISAR NEO drug-eluting stents are safe and work well for adults having percutaneous coronary intervention for coronary artery disease.

  Recruiting at 7 sites Asan Medical Center · Seoul, Songpa-gu and 10 other locations · NCT06177743

• μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease

  This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.

  Recruiting Centro Cardiologico Monzino · Cosenza, CS and 3 other locations · NCT07917234

• Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents

  This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.

  Recruiting Adiyaman University · Adıyaman · NCT07898215

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.